Why Liquidia Stock Was Diving This Week

LQDA dropped 20% this week despite beating second-quarter revenue expectations with $171.7 million against a $171 million consensus and posting net profit of $74.7 million. The sell-off followed a 155% year-to-date rally that left the stock vulnerable to profit-taking when results failed to exceed what bulls had priced in.

The company's pulmonary hypertension treatment Yutrepia continues to drive growth, but the single-molecule concentration presents portfolio risk. The disconnect between strong fundamentals and price action reflects the challenge of sustaining momentum after a triple-digit run.